Status:
COMPLETED
Cysteine-lowering Treatment With Mesna
Lead Sponsor:
University of Oslo
Collaborating Sponsors:
Oslo University Hospital
University of Oxford
Conditions:
Obesity
Drug Effect
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
The primary objective of this study is to determine the efficacy of the drug Mesna® (Uromitexan) in healthy participants with overweight or obesity with respect to change in plasma concentrations of t...
Detailed Description
In both animal experiments and human studies, cysteine in the blood is strongly associated with obesity. In rodents, changes in cysteine induced by dietary means are accompanied by changes in fat mass...
Eligibility Criteria
Inclusion
- BMI between BMI 27-40 kg/m2
- Age between 18-55 years
- Male
- Healthy as determined by medical evaluation, medical history, physical examination, 12-lead ECG, and laboratory tests
Exclusion
- Presence of chronic disease
- Chronic drug use
- Past or intended use of over-the-counter or prescription medication including herbal medications within 14 days prior to dosing
- Veganism
- Strenuous physical activity ≥3 times every week
- Smoking
Key Trial Info
Start Date :
November 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2021
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT04449536
Start Date
November 2 2020
End Date
October 21 2021
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oslo
Oslo, Norway